EGFR and non-small cell lung carcinoma: In the recently reported ADAURA study, adjuvant osimertinib demonstrated a 79% reduction in the disease recurrence risk or death in resected stage IB-IIIA EGFR-mutated NSCLC patients (DFS HR 0.21, 95% CI 0.16–0.28, p < 0.0001) [114].